Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY

Start Learning

Touch Loading image
JOURNALS
Start Learning
Immunotherapeutic Advances in the Treatment of Merkel Cell Carcinoma
Munich Germany
JOURNALS
Start Learning
Highlights from ESMO GI 2024
touchCONGRESS
Start Learning
Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024
touchCONGRESS
Start Learning
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
CE/CME ACCREDITED
JOURNALS
Start Learning
Long-term Survival in Patients with Advanced Hepatocellular Cancer with Dual Immunotherapy Agents: Tremelimumab Plus Durvalumab
CONFERENCE HUB
Start Learning
Transarterial chemoembolization with lenvatinib and pembrolizumab showed improvement in progression-free survival for hepatocellular carcinoma
CONFERENCE HUB
Start Learning
Durvalumab with neoadjuvant chemotherapy and radical cystectomy in muscle-invasive bladder cancer
CONFERENCE HUB
Start Learning
Trastuzumab deruxtecan shows clinical benefit in patients with HER2-ultralow metastatic breast cancer
Esophagus or oesophagus 3D rendering illustration close-up with male body contours. Human anatomy, esophagitis, acid reflux, digestive system, medical, biology, science, medicine, healthcare concepts.
JOURNALS
Start Learning
Advancements in Immune Checkpoint Inhibitors for Oesophageal Squamous Cell Carcinoma: Current Status and Future Perspectives
touchMEETING HIGHLIGHTS
Start Learning
A voyage of discovery: Exploring the latest evidence for 1q21+
Sponsored content

to view Favourites, Keep Notes and Track CME Credits

Favourites
Clinical advancements and key presentations: ESGO 2024
View
Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs
View
Foreword – touchREVIEWS in Oncology & Haematology, Volume 20, Issue 1, 2024
View
Advancements in Immune Checkpoint Inhibitors for Oesophageal Squamous Cell Carcinoma: Current Status and Future Perspectives
View
A personal drive to make a difference: Dr Michael K. Gibson’s career in gastrointestinal oncology
View
Capivasertib + paclitaxel for metastatic triple-negative breast cancer did not meet threshold for improving overall survival
View
Breast cancer highlights: DESTINY-Breast06, postMONARCH, TBCRC 048
View
Navigating treatment choices in high-risk early-stage melanoma
View
Fruquintinib in Patients with Previously Treated Metastatic Colorectal Cancer
View
ESMO Congress 2024 – 13 – 17 September, Barcelona Spain
View
In Partnership with...
Useful Links:
About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
Connect With Us:

Other websites from Touch Medical Media:

touchONCOLOGY
touchOPHTHALMOLOGY
touchENDOCRINOLOGY
touchNEUROLOGY
touchCARDIO
touchRESPIRATORY
touchIMMUNOLOGY
touchINFECTIOUS DISEASES
touchHAEMATOLOGY
touchDERMATOLOGY

Copyright® 2025 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup